Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kissei Braced for 65% Sales Fall for Urief on Generic Onslaught; Exec Admits Uphill Battle for Nesp Biosimilar
May 9, 2019
- Sumitomo Dainippon to Set Up Cell Therapy Hub in San Diego
May 9, 2019
- DS-8201 Delivers in PII Breast Cancer Study: Daiichi Sankyo/AZ
May 9, 2019
- Eisai Kicks Off Joint Program with UK Institution to Support Dementia Research
May 9, 2019
- Bioverativ Japan Now Merged into Sanofi
May 8, 2019
- Eisai, Purdue Wind Up Partnership for Insomnia Drug Lemborexant
May 8, 2019
- Shionogi, AI Startup Tie Up to Develop Influenza Diagnostic Device
May 8, 2019
- Japan Generic Market to Reach 1.2 Trillion Yen by 2022, Biosimilars, AG Market to Expand Too: Fuji Keizai
May 7, 2019
- Daiichi Sankyo Skips Pre-Verification for Vaccine Sterility Test, No Safety Concerns Found
May 7, 2019
- Boehringer Workforce Dwindles by 500 in Japan, MSD by 300: Jiho Survey
May 7, 2019
- Dupixent Now Available for Self-Injection
May 7, 2019
- Daiichi Sankyo Exercises Option to Commercialize Bispecific Antibodies Based on Joint Research with Zymeworks
May 7, 2019
- After Biogen Pullout, Salix Picks Up Rights to Mitsubishi Tanabe’s MT-1303
May 7, 2019
- Dupixent Filed for Sinusitis in Japan: Sanofi
May 7, 2019
- Astellas Looks to Fortify China Biz via Global Commercial Rejig
April 26, 2019
- Astellas’ Net Profit Soars 35% on Xtandi, Betanis
April 26, 2019
- Daiichi Sankyo Reels from Olmesartan LOE, Logs 3.2% Sales Fall
April 26, 2019
- Daiichi Sankyo to Move Up Japan Filing of DS-8201 to FY2019 H2
April 26, 2019
- CSL Behring Seeks Additional Indication for Privigen
April 26, 2019
- Ninlaro Filed in Japan for Post-Transplant Maintenance: Takeda
April 26, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…